

## 35Pharma Appoints Guy Braunstein, MD, PhD, to its Board of Directors

- Guy Braunstein, MD, PhD is an experienced CMO who previously led global clinical development at multiple Pharma and biotech companies, including as Head of Global Clinical Development at Actelion until its \$30 billion acquisition.
- Graham Walmsley, MD, PhD, Managing Member and Co-Founder of Logos Capital, also joins the Company's board as an observer.
- Strengthening of the board will support clinical development of the Company's Activin and GDF traps and follows a previously completed Series B financing led by Logos Capital and a Series A financing led by venBio Partners.

**Montreal, QC, Canada (Jan 25, 2024)** – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced the appointment of seasoned drug development executive Guy Braunstein, MD, PhD, to its Board of Directors. Graham Walmsley, MD, PhD, also joined the board as an observer.

“Guy’s successful track record in rapidly progressing numerous agents from early clinical trials to registration is unparalleled,” said Walter Blättler, PhD, 35Pharma’s Chairman. “His extensive drug development leadership expertise will help guide our drug candidates to expeditious clinical validation.”

Dr Braunstein added: “35Pharma is well positioned for near-term clinical validation of their Pulmonary Hypertension, Heart Failure and obesity pipeline. I am extremely enthusiastic about joining the Company at this critical time and supporting the team to rapidly demonstrate the clinical value of these highly differentiated agents with disease modifying potential.”

Dr Braunstein’s appointment follows a previously completed Series B financing led by Logos Capital with participation from Surveyor, Marshall Wace as well as venBio Partners and other existing investors. Dr Walmsley, Managing Member and Co-Founder of Logos Capital, commented: “35Pharma’s unique receptor ectodomain technology can unlock the powerful Activin biology across multiple high-value indications. I look forward to a clinical catalyst-rich 2024 and to working with Guy and the rest of the board to support 35Pharma during this exciting period.”

Richard Gaster, MD, PhD, Managing Partner at venBio, who led the Company’s Series A financing, added: “We take immense pride in our early partnership with 35Pharma, particularly in their groundbreaking ectodomain traps pipeline. The remarkable progress achieved so far fuels our excitement. As we look ahead, we eagerly await clinical proof-of-concept readouts across their extensive development programs, set to begin in 2024.”

**Guy Braunstein, MD, PhD**, is a trained pulmonologist and was a member of the Executive Committee and Head of Global Clinical Development at Actelion up until its \$30 billion acquisition by Janssen. While at Actelion, Dr Braunstein led the development and ultimate approval of several branded drugs for the treatment of Pulmonary Hypertension, establishing Actelion as the PAH market leader. Dr Braunstein's background also includes the CMO position at Merck Serono, CMO International at Serono, as well as medical executive positions at Astra, Fisons, Rhône-Poulenc Rorer, Glaxo Wellcome, GSK and Chiron. Currently, Dr Braunstein serves



as Executive VP and Chief Medical Officer at Idorsia Ltd, where he has been integral to rapidly advancing the company's broad clinical pipeline, achieving the first registration less than five years after the company's inception. Over his more than three-decades long industry career, Dr Braunstein led to approval and line extensions of numerous medicines across a diverse group of therapeutic areas.

### **About 35Pharma**

35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.

### **Contact**

Julia Schoelermann, VP Corporate Development, 35Pharma  
info@35pharma.com

For more information, please visit [www.35pharma.com](http://www.35pharma.com)